Use policy
Introduction
The prevalence of polypharmacy continues to rise in the Unites States and elsewhere around the world. With the global aging of the population, we are seeing a shift to a population with comorbidity and subsequent increased medication use. More than half of people over 65 in the United Stated have 3 or more chronic conditions. 1 In the United States the population >65 years in 2010 was 13%; by 2030 the older population is projected to reach 20%, while in other developed countries, older people are expected to reach >30% of the population by 2030. 2 Increasing medication use is not only on the rise because of higher proportions of older people in the population, but also because more and more older people are exposed to polypharmacy. Based on recent US survey data, >90% of people 65 years and older took at least 1 prescription medication in the prior 30 days, and 39% of older people take 5 or more regular medications on a chronic basis. 3 In the UK, recent registry data shows that 24% of people 80 years and older take 10 or more medications regularly. 4 While the use of multiple medicines is necessary to treat multiple conditions, taking increasing numbers of medications conveys increasing risks of harm to older patients. Studies of polypharmacy have used different definitions and different methodologies to define the exposure of harmful polypharmacy, and have evaluated different outcomes as measures of harm. There is support to use the definition for polypharmacy as using 5 or more medications; polypharmacy in this regard has been shown to be harmful due to the increased risk of adverse drug events, adverse outcomes, and drug interactions. 5, 6 Despite inconsistencies and heterogeneities in study design, polypharmacy has been shown, primarily in observational studies, to be associated with an increased risk of adverse drug events, hospitalizations, and falls. 7 In addition, the use of multiple medications is associated with an increased likelihood of important therapeutic 4 omissions through non-adherence?, such as beneficial treatments for heart failure or hypertension. 8 It is unknown whether a reduction in polypharmacy results in improved patient outcomes, but there has been increasing interest in the reduction in medication number as a means to mitigate the harmful effects of polypharmacy. 7 Given the increasing likelihood that healthcare providers will be faced with the complexity of care for adults with multimorbidity and the increasing concerns about the harms of polypharmacy, a greater focus has been placed on deprescribing as an approach to rationalize medication therapy. 9 The purpose of this review is to briefly summarize the definition of deprescribing, review the process of deprescribing, to discuss the role of patient-centered care in guiding deprescribing interventions, and to discuss barriers and possible solutions to deprescribing.
What is deprescribing?
While many terms have been used to describe the process of stopping medications, including discontinuation, withdrawal, cessation, stopping, and even debridement, the universal use of the term "deprescribing" has been suggested moving forward to provide consistency. 9, 10 While there are some variations in the definition of deprescribing, common features are the focus on stopping medications based on lack of benefit or increased risk. Definitions include the cessation of a medication no longer necessary, 11 a process of reducing or stopping medications that are harmful or unnecessary, 12 a planned process of stopping medications that are no longer beneficial, 13 and a process of "tapering, stopping, discontinuing, or withdrawing drugs". 10 A recent systematic review and network analysis synthesized the various definitions and proposed the following as a definition of deprescribing: 
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The focus of this definition is on deprescribing being a process; as has been previously recommended, the medication use process must integrate prescribing and deprescribing. 14 Medications that are candidates for reduction, by this definition, are "inappropriate", which could have different meanings depending on the clinical situation, and would be identified based on being high risk, low benefit, or both.
Deprescribing has been shown to be feasible and generally safe, although the possibility of exacerbating the underlying condition being treated should not be discounted -particularly when the condition involves the cardiovascular or central nervous system. 15, 16 Indeed, a recent systematic review of deprescribing interventions found that it was generally feasible, resulted in reduced medication number and minimized inappropriate medication use. (1) those with the greatest harm and least benefit;
The process of deprescribing
(2) those easiest to discontinue, ie, lowest likelihood of withdrawal reactions or disease rebound; (3) those that the patient is most willing to discontinue first (to gain buy-in to deprescribing other drugs)
-Suggested approach is to rank drugs from high harm/low benefit to low harm/high benefit and discontinue the former in sequential order Scott also proposes an algorithm to determine the order and the mode by which medications could be discontinued.
Patient preferences for deprescribing
The process of deprescribing requires active assessment of patients' attitudes and preferences along the way. For example, patients should be asked whether they think a medication is helpful, if it causing side effects or burden and, ultimately, if they prefer to continue it. Medications that are eligible to be deprescribed and that a patient is willing to stop should be prioritized for deprescribing first, in order to gain patient buy-in and trust during the process.
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In adults with multimorbidity, in whom benefits and risks of medication therapy are uncertain, and benefits or risks of stopping medications are also uncertain, deprescribing could be considered a preference-sensitive decision, in which patients' goals and preferences for care
should be highly influential in the decision-making process. 1 Identifying medications that are eligible to be deprescribed may be based on an inappropriate benefit-risk ratio, in addition to the complexity and feasibility of the medication regimen, and the alignment with goals and 11 preferences for care. A proposed framework to identify candidate drugs to stop in such patients is shown in Figure 2 . What do patients think about deprescribing? Surprisingly, few qualitative studies have specifically explored patients' attitudes toward deprescribing. A study of the perspectives of long-term care residents and healthcare professionals suggested that to be successful, deprescribing interventions need to take into account the perspectives of multiple stakeholders. 23 For residents in particular, highly ranked concerns included their well being, continuity of care and communication, the ability to continue medications that contributed to their feeling of wellness, the ability to stop medications they believed to be burdensome, having their voices and rights respected, and respecting the opinions of their physicians. 23 A study of frail long-term care residents and healthcare professionals in Australia found a significant disconnect between the perceptions of medication benefits on the part of residents and their family members, whereas physicians recognized that for frail older patients, long-term care was essentially palliative. 24 In addition, residents had poor understanding about the indications and possible adverse effects of their medications, low self-efficacy around medication discontinuation, and high trust in their physician to make medication decisions. 24 Similarly, a study of 85 patients with heart failure and 74 prescribing physicians found a disconnect regarding deprescribing; most of the patients were not dissatisfied about the number of medicines they took regularly, and only 41% could identify at least one drug they would stop, whereas physicians had a high consensus about drugs that could be stopped when presented with clinical heart failure scenarios. 25 In contrast, a study 13 exploring the medication-related views of patients with life-limiting illness as well as their caregivers found that there was acknowledgement that medications were burdensome, and there was a willingness to rationalize medication use, particularly when they were exposed to polypharmacy. 26 Patients and caregivers also recognized that a transition in care, potentially after the diagnosis of life-limiting illness, was a time when less importance was placed on taking preventive medications, with a willingness to change medications at such transitions. 26 Trials associated with deprescribing interventions have not consistently explored patient preferences, perceptions or experiences. A recent systematic review included 21 randomized controlled trials (RCTs) on deprescribing specific drugs (rather than an overall approach to reducing medication number), including antipsychotics, diuretics, antidepressants, digoxin, statins, and drugs for benign prostatic hyperplasia. They found that in many of the trials, deprescribing medications led to a relapse or worsening of symptoms or the underlying disease state. The review did, however, not specifically address patient preferences or patient-specific outcomes. 16 In a trial of stopping proton pump inhibitors (PPIs), of 72 patients considered for PPI withdrawal, 8 were considered appropriate to deprescribe, 6 consented, of whom 3 stopped the drug and 3 reduced the dose. Three of the 6 participants returned feedback and reported that they were comfortable with the process and willing to have another medication similarly deprescribed. 11 A cross-sectional study of patients in the last few days of life in a geriatric ward in Belgium found that deprescribing of inappropriate medications at the end of life was more frequent if death was expected, and the authors noted further opportunity to optimize medication use by deprescribing drugs at the end of life. They particularly noted that in cases where prognostication is difficult, early discussions of patient's preferences and wishes for end of life care could help to engender trust with the physician and facilitate the process of deprescribing To specifically address patients' willingness to undertake deprescribing, Reeve, et al.
developed the Patients' Attitudes Towards Deprescribing questionnaire. 28 The PATD was then employed in an ambulatory setting in a sample of adults, 65% of whom were over 65 years old, and 92% reported willingness to have one or more medications stopped. 29 The PATD was applied in a population of older hospitalized patients in Italy, and found that most of the patients felt that they were taking too many medications, and 89% were willing to have one of their regular medicines deprescribed. 30 The PATD was also applied specifically around stopping statins on older inpatients in Australia, and found that 89% of the participants were willing to stop one or more of their regular medications, and 95% were willing to stop statins. 31 Patients' willingness to deprescribe may not be enough. Indeed, based on results from qualitative studies highlighting the need for more communication and a focus on patient well being, and based on quantitative studies showing lower uptake of deprescribing interventions and concerns for relapse of underlying symptoms, a successful deprescribing intervention must seek to fully engage both the patient and, where relevant, the caregiver. The EMPOWER trial is an example to describe such an approach: this intervention was developed toward increasing patients' knowledge and self-efficacy around stopping benzodiazepines, and was designed to create a cognitive dissonance around the perception that harmful medications were safe. 32 The intervention consisted of a booklet with an assessment about medication risks, education about harms and drug interactions, and a specific step-wise tapering protocol. Overall, 86% completed a 6-month follow up, at which point 27% of the intervention group had stopped the 15 benzodiazepine, compared to only 5% of the control group (who received general educational materials). This approach has been expanded to other classes of drugs, with publicly available deprescribing algorithms for practitioners to employ.
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Barriers and pitfalls to deprescribing
Despite the perceived acceptability of deprescribing and the momentum toward reducing medication use, there are significant barriers to stopping medications. The biggest barrier to deprescribing is an emotional and psychological one: our belief as a society and healthcare system that every patient-doctor interaction needs to end in the addition of a medication, and that additional medication will either prolong life or promote health. 34 Much has been written about prescribers' discomfort in stopping medications, and emerging discussion of these barriers incorporates a consideration of patient and system barriers to the process. 35 While there is a disconnect between patients and prescribers regarding the belief about the benefit of medications, the widespread dislike of overmedication is a major enabler of deprescribing as an acceptable intervention. 35 Recent evidence regarding the willingness of patients to stop medications and their reliance on physicians to communicate the need to stop drugs puts the onus back on prescribers to take on responsibility to make deprescribing more commonplace. 18 The barriers to deprescribing are summarized in the Box. Prescribers' opinions vary widely, particularly about preventive medications, highlighting the need for consensus guidelines around deprescribing. 12 The optimal time at which to deprescribe, the ideal patient situations in which deprescribing should occur, and the ideal settings are unclear and may very widely based on the individual clinical situation. For example, while transitions of care may represent an ideal time to reconcile and critically rethink all medication therapy, deprescribing in the hospital could be a problem for sustaining change.
Box. Potential Barriers to Deprescribing
Deprescribing requires active participation of the patient, including communication and agreement to the change, and an acutely ill patient may not be able to participate in 17 deprescribing. 38 Similarly, the ideal patient situations that should prompt deprescribing are uncertain. As an example, patients with dementia may have frequently changing goals of care, making deprescribing necessary as care shifts at the end of life; however, the inability to engage the patient in deprescribing and the need to engage caregivers with frequent communication may present obstacles. 36 Ultimately, addressing these specific barriers could help to facilitate deprescribing and make stopping medications as facile as prescribing them in the first place. This could be accomplished by a number of changes, not the least of which includes:
1) Systematically screen patients for their willingness to have medications deprescribed. Much in the same way that providers systematically screen for depression or for falls, tools such as the PATD could be employed to elicit a patient's attitudes, which could help inform providers about preferences and could facilitate patient-centered decision-making about medicines. 28 2) Provide health information systems that facilitate communication between multiple specialists and with the patient and caregiver, to reduce the concerns about stopping medicines that other prescribers have started.
3) Leverage data systems to identify medications that are eligible for deprescribing or patients that are ideal candidates for deprescribing interventions. 39 This could be accomplished through the use of existing tools to identify inappropriate medications and tools to identify patients with high-risk conditions. 4) Promote reimbursement for deprescribing activities by members of a multidisciplinary team, and specifically facilitate the input of pharmacists in making recommendations to deprescribe. 18 5) Strengthen the evidence based around deprescribing by including patient goal-driven interventions and patient-reported outcomes in deprescribing studies.
Conclusions
Deprescribing is more complex than simply stopping medications: it is a multiple stage process that should be patient-centred and a part of the wider remit of shared care decisionmaking. Despite the acknowledgment that patient preferences -alongside those of healthcare professionals and caregivers -are crucial for any successful deprescribing intervention there is, at present, a dearth of literature in this area. Future studies -particularly randomized controlled trials -should be encouraged to include a qualitative aspect to enable the better understanding of perceptions and experiences for patients who have undergone deprescribing interventions. It will be crucial for future deprescribing interventions to be able to adapt to new evidence as it emerges and still allow for the application of clinical judgment and the consideration of ethical issues.
